Council tax bills set to rise at fastest rate for two decades, economist warns

Paul Johnson said that local government in England did 'perhaps a little bit better than it might have expected' out of the Chancellor's statement on Wednesday, but the 'sting in the tail' is the assumption that 'council tax bills will rise by 5% a year' as part of the funding.
The core spending power of councils is set to increase by 2.6% a year from next year, and 'if English councils do choose 5% increases – and most almost certainly will – council tax bills look set to rise at their fastest rate over any parliament since 2001-05', Mr Johnson said on Thursday.
On Wednesday, Ms Reeves said that ministers will not be 'going above' the 5% annual increases in council tax.
She told ITV: 'The previous government increased council tax by 5% a year, and we have stuck to that. We won't be going above that.
'That is the council tax policy that we inherited from the previous government, and that we will be continuing.'
The biggest winner from Wednesday's statement was the NHS, which will see its budget rise by £29 billion per year in real terms.
Ruth Curtice, the chief executive of the Resolution Foundation, has said that Britain is turning into a 'National Health State'.
Overnight, the think tank said Ms Reeves' announcements had followed a recent trend that saw increases for the NHS come at the expense of other public services.
Ms Curtice said: 'Health accounted for 90% of the extra public service spending, continuing a trend that is seeing the British state morph into a National Health State, with half of public service spending set to be on health by the end of the decade.'
Defence was another of Wednesday's winners, Ms Curtice said, receiving a significant increase in capital spending while other departments saw an overall £3.6 billion real-terms cut in investment.
The Institute for Fiscal Studies (IFS) made similar arguments about 'substantial' investment in the NHS and defence coming at the expense of other departments, although Mr Johnson warned on Wednesday the money may not be enough.
In his snap reaction to the review, Mr Johnson said: 'Aiming to get back to meeting the NHS 18-week target for hospital waiting times within this Parliament is enormously ambitious – an NHS funding settlement below the long-run average might not measure up.
'And on defence, it's entirely possible that an increase in the Nato spending target will mean that maintaining defence spending at 2.6% of GDP no longer cuts the mustard.'
Ms Curtice added that low and middle-income families had also done well out of the spending review 'after two rounds of painful tax rises and welfare cuts', with the poorest fifth of families benefiting from an average of £1,700 in extra spending on schools, hospitals and the police.
She warned that, without economic growth, another round of tax rises was likely to come in the autumn as the Chancellor seeks to balance the books.
She said: 'The extra money in this spending review has already been accounted for in the last forecast.
'But a weaker economic outlook and the unfunded changes to winter fuel payments mean the Chancellor will likely need to look again at tax rises in the autumn.'
Speaking after delivering her spending review, Ms Reeves insisted she would not have to raise taxes to cover her spending review.
She told GB News: 'Every penny of this is funded through the tax increases and the changes to the fiscal rules that we set out last autumn.'
Conservative leader Kemi Badenoch described rising health spending as a 'conundrum', with a similar approach having been taken 'again and again' as she spoke at a business conference in central London on Thursday morning.
In reference to a pro-Brexit campaign stunt, Mrs Badenoch said: 'I mean, who remembers the side of a red bus that said 'we're going to give the NHS £350 million more a week'?
'Many people don't know that we did that. We did do that, and yet, still we're not seeing the returns.
'We've put more and more money in, and we're getting less and less out.'
The Government have not explained how and why the NHS will be better as a result of its spending plans, the Tory leader added, and claimed the public know 'we need to start talking about productivity reforms, public sector reforms'.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Leader Live

42 minutes ago

• Leader Live

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

The Herald Scotland

an hour ago

• The Herald Scotland

Weight loss pill shows promise in new trial

And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. GPs in England will be able to prescribe Mounjaro from Monday (Alamy/PA) An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

North Wales Chronicle

an hour ago

• North Wales Chronicle

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.